Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name PDGFRA D842V
Gene Variant Detail

PDGFRA D842V (gain of function)

Relevant Treatment Approaches PDGFR Inhibitor (Pan) PDGFR-alpha Inhibitor Avapritinib

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRA D842V Advanced Solid Tumor sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) inhibited proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 31085175). 31085175
PDGFRA D842V gastrointestinal stromal tumor predicted - sensitive PDGFR Inhibitor (Pan) Regorafenib Clinical Study - Cohort Actionable In a clinical study, Stivarga (regorafenib) treatment resulted in partial response in 11% (2/18) of patients and stable disease in 39% (7/18) of gastrointestinal stromal tumor patients, including prolonged stable disease for 12 months in a patient harboring PDGFRA D842V (PMID: 25905001). 25905001
PDGFRA D842V gastrointestinal stromal tumor resistant PDGFR Inhibitor (Pan) Imatinib Guideline Actionable Gleevec (imatinib) is not indicated for use in gastrointestinal stromal tumor (GIST) patients with PDGFRA D842V mutations (NCCN.org). detail...
PDGFRA D842V Advanced Solid Tumor decreased response PDGFR Inhibitor (Pan) Regorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated reduced response to growth inhibition by Stivarga (regorafenib) compared to GIST cells harboring KIT exon 11 deletion in culture (PMID: 31085175). 31085175
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Nilotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084). 18794084
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Nilotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 30389923). 30389923
PDGFRA D842V gastrointestinal stromal tumor sensitive PDGFR Inhibitor (Pan) Dasatinib Guideline Actionable Sprycel (dasatinib) is included in the guidelines for patients with gastrointestinal stromal tumor (GIST) with PDGFRA D842V mutations (NCCN.org). detail...
PDGFRA D842V gastrointestinal stromal tumor sensitive PDGFR Inhibitor (Pan) Dasatinib Phase 0 Actionable In a clinical trial, Sprycel (dasatinib) treatment resulted in a partial response in 25% (12/48) of patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor, with decreased tumor size in 2 of those patients, 1 of which harbored PDGFRA D842V (PMID: 29710216). 29710216
PDGFRA D842V gastrointestinal stromal tumor sensitive PDGFR Inhibitor (Pan) Crenolanib Phase Ib/II Actionable In a Phase I/II trial, treatment with Crenolanib (CP-868596) resulted in a clinical benefit rate of 31% (5/16) in gastronintestinal stromal tumor patients harboring PDGFRA D842V, with partial response in 2/16 and stable disease in 3/16 patients (J Clin Oncol 34, 2016 (suppl; abstr 11010)). detail...
PDGFRA D842V Advanced Solid Tumor sensitive Avapritinib PDGFR-alpha Inhibitor Avapritinib Preclinical - Cell culture Actionable In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation in transformed cells overexpressing PDGFRA D842V in culture (PMID: 29093181). 29093181
PDGFRA D842V Advanced Solid Tumor sensitive GSK2126458 Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923). 30389923
PDGFRA D842V gastrointestinal stromal tumor sensitive Avapritinib PDGFR-alpha Inhibitor Avapritinib Guideline Actionable Ayvakit (avapritinib) is included in the guidelines for patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutations, including PDGFRA D842V (NCCN.org). detail...
PDGFRA D842V gastrointestinal stromal tumor sensitive Avapritinib PDGFR-alpha Inhibitor Avapritinib Phase I Actionable In a Phase I trial (NAVIGATOR), Ayvakit (avapritinib) treatment in patients with a gastrointestinal stromal tumor harboring PDGFRA D842V resulted in an overall response in 88% (49/56), with 5 patients experiencing a complete response (9%) and 44 patients with a partial response (79%) (PMID: 32615108; NCT02508532). 32615108
PDGFRA D842V gastrointestinal stromal tumor sensitive Avapritinib PDGFR-alpha Inhibitor Avapritinib FDA approved Actionable In a Phase I trial (NAVIGATOR) that supported FDA approval, Ayvakit (avapritinib) treatment resulted in an objective response in 86% (37/43, 3 complete response, 34 partial response) and stable disease in 12% (5/43) of patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including D842V, with median duration of response not reached (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 11022-11022; NCT02508532). detail... detail...
PDGFRA D842V gastrointestinal stromal tumor sensitive Avapritinib PDGFR-alpha Inhibitor Avapritinib Case Reports/Case Series Actionable In a Phase I trial, Ayvakit (avapritinib) treatment resulted in partial response lasted for more than 15 cycles of treatment, and sustained reduction of plasma PDGFRA D842V in a patient with gastrointestinal stromal tumor harboring PDGFRA D842V, whose disease had progressed on previous Gleevec (imatinib mesylate), Sprycel (dasatinib), and Crenolanib treatment (PMID: 29093181; NCT02508532). 29093181
PDGFRA D842V Advanced Solid Tumor sensitive PDGFR-alpha Inhibitor Ripretinib Preclinical - Cell culture Actionable In a preclinical study, Qinlock (ripretinib) inhibited proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 31085175). 31085175
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Imatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 30389923). 30389923
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Imatinib Preclinical Actionable In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335). 15928335
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Sunitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923). 30389923
PDGFRA D842V Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Sunitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458). 18955458
PDGFRA D842V Advanced Solid Tumor sensitive PDGFR Inhibitor (Pan) Crenolanib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated sensitivity to Crenolanib in culture, resulting in decreased cell proliferation (PMID: 30389923). 30389923
PDGFRA D842V Advanced Solid Tumor sensitive PDGFR Inhibitor (Pan) Crenolanib Preclinical - Cell culture Actionable In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105). 22745105
Clinical Trial Phase Therapies Title Recruitment Status
NCT02847429 Phase III Crenolanib Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST Recruiting